{"id":"NCT00472797","sponsor":"EMD Serono","briefTitle":"Rebif New Formulation (RNF) Quality of Life (QOL) Study","officialTitle":"A Randomized, Multicenter, Two-arm, 12 Week Phase IIIb Study to Evaluate Quality of Life (QOL) Measures in Subjects With Relapsing Forms of Multiple Sclerosis (MS) Who Are Transitioning From RebifÂ® (Interferon Beta-1a) to Rebif New Formulation (RNF)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2007-04","primaryCompletion":"2009-02","completion":"2009-11","firstPosted":"2007-05-14","resultsPosted":"2009-09-02","lastUpdate":"2013-08-07"},"enrollment":232,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"SUPPORTIVE_CARE"},"conditions":["Relapsing Multiple Sclerosis"],"interventions":[{"type":"DRUG","name":"Rebif New Formulation Non Titrated","otherNames":[]},{"type":"DRUG","name":"Rebif New Formulation Titrated","otherNames":[]}],"arms":[{"label":"1","type":"ACTIVE_COMPARATOR"},{"label":"2","type":"ACTIVE_COMPARATOR"}],"summary":"To evaluate the impact on Quality of Life (QOL), tolerability, treatment satisfaction, and injection site redness Rebif treated subjects with relapsing forms of MS who transition to a new formulation of Rebif (RNF).","primaryOutcome":{"measure":"Percent Change in Global Side Effects (GSE) on Multiple Sclerosis Treatment Concerns Quesionnaire (MSTCQ)","timeFrame":"% change from Baseline to Week 12","effectByArm":[{"arm":"All New Formulation of Rebif Subjects","deltaMin":5,"sd":17.7}],"pValues":[{"comp":"OG000","p":"<0.001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":1,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":["http://www.mslifelines.com"]},"adverseEventsSummary":{"seriousAny":{"events":10,"n":118},"commonTop":["Headache","Pain","Influenza-like Illness","Nasopharyngitis","Urinary tract infection"]}}